Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).
Mathias Rummel(Universitätsklinikum Gießen und Marburg), Wolfram Brugger(University of Freiburg), Ulrich Kaiser(University of Applied Sciences Landshut), Georg Maschmeyer(Radboud University Medical Center), Dorothea Kofahl-Krause(Medizinische Hochschule Hannover), Fritz Roller(Justus-Liebig-Universität Gießen), Axel Hinke, N. Niederle(Klinikum Leverkusen), Harald Balló(Praxis für Hämatologie und Onkologie), Dieter Hoelzer(Endokrinologikum), Juergen Barth(Justus-Liebig-Universität Gießen), Eckhart Weidmann(Krankenhaus Nordwest), Manfred Welslau(Klinikum Aschaffenburg), Gerhard Heil(Goethe University Frankfurt), A. Banat(Justus-Liebig-Universität Gießen), Heinz A. Duerk, Christina Balser(Philipps University of Marburg), Christoph Losem, Ulrich von Gruenhagen(Praxis für Hämatologie und Onkologie)
Cited by 157
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k